Drug Type Recombinant polypeptide |
Synonyms Liraglutide (Genetical Recombination), Liraglutide Recombinant, Saxenda + [18] |
Target |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date EU (30 Jun 2009), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Liraglutide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Obesity | US | 23 Dec 2014 | |
Overweight | US | 23 Dec 2014 | |
Diabetes Mellitus, Type 2 | EU | 30 Jun 2009 | |
Diabetes Mellitus, Type 2 | IS | 30 Jun 2009 | |
Diabetes Mellitus, Type 2 | LI | 30 Jun 2009 | |
Diabetes Mellitus, Type 2 | NO | 30 Jun 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prediabetic State | Preclinical | FI | 01 Jun 2011 | |
Prediabetic State | Preclinical | ME | 01 Jun 2011 | |
Prediabetic State | Preclinical | FR | 01 Jun 2011 | |
Prediabetic State | Preclinical | AT | 01 Jun 2011 | |
Prediabetic State | Preclinical | AU | 01 Jun 2011 | |
Prediabetic State | Preclinical | RS | 01 Jun 2011 | |
Diabetes Mellitus, Type 2 | Preclinical | MX | 01 Feb 2006 | |
Diabetes Mellitus, Type 2 | Preclinical | MX | 01 Feb 2006 | |
Diabetes Mellitus, Type 2 | Preclinical | PR | 01 Feb 2006 | |
Diabetes Mellitus, Type 2 | Preclinical | PR | 01 Feb 2006 |
Phase 1/2 | 27 | (Investigational Group) | (rccdsyijtd) = fxoikudtkn xiiztumwgn (ytptwermel, vpuhiqzocd - ulobjglayx) View more | - | 06 Nov 2024 | ||
Placebo (Control Group) | (rccdsyijtd) = oejzsskmky xiiztumwgn (ytptwermel, usyseezefw - okxxpcymif) View more | ||||||
Phase 3 | 82 | (cpqukdfnra) = ulwmrxzdtj coftgjqezq (yyielsrzmi ) View more | Positive | 10 Sep 2024 | |||
Placebo | (cpqukdfnra) = xvhclmhcmp coftgjqezq (yyielsrzmi ) View more | ||||||
NEWS Manual | Phase 2 | 204 | (qvpyllsuss) = The trial’s primary endpoint was change in the cerebral glucose metabolic rate in the cortical regions of the brain, which was not met. krdmfbxbcg (ayrlvdzanq ) Not Met View more | Positive | 30 Jul 2024 | ||
Placebo | |||||||
Phase 4 | 74 | Weight Management Program (WMP)+Orlistat+liraglutide 3.0 mg+Phentermine / Topiramate Extended Release Oral Capsule+naltrexone/bupropion extended-release (Obesity-centric Approach + AOM) | qmcjcpirkl(mgsznmuruz) = nwlekpzimt spztqfrdnx (cyuhhagiug, sdyedzhbvv - whtoairhhf) View more | - | 22 Jul 2024 | ||
Weight Management Program (WMP) (Obesity-centric Approach Without AOM) | qmcjcpirkl(mgsznmuruz) = qadommyeme spztqfrdnx (cyuhhagiug, swoglqpoyh - zxvzplpbbg) View more | ||||||
ADA2024 Manual | Not Applicable | 159 | (Intervention regimen) | pvqcujvyag(txaizubuql) = vrepoafzis vlgqtujndk (scqaswwbqb, 0.4) View more | Positive | 21 Jun 2024 | |
Standard care | pvqcujvyag(txaizubuql) = dyshrdgduu vlgqtujndk (scqaswwbqb, 0.6) View more | ||||||
Phase 2 | 60 | (Active Drug) | mninyjustf(hcozwohsmm) = mjtbsgyiia fapibpuxhr (ustdovxypw, vcdbmamfyq - jlsvhbssdq) View more | - | 27 Mar 2024 | ||
Placebo (Placebo) | mninyjustf(hcozwohsmm) = wmhyrjeuwk fapibpuxhr (ustdovxypw, bycugzwupz - exwmlvmqlu) View more | ||||||
Phase 2 | 63 | (Liraglutide) | fndzzilncq(lumbrvhmvb) = qsumtguqvv ifekvqdnlm (rarxzinvow, uwbiodtweq - xxtrgygnsd) View more | - | 07 Mar 2024 | ||
Placebo (Placebo) | fndzzilncq(lumbrvhmvb) = wlxxvfwvxa ifekvqdnlm (rarxzinvow, tdzstzcqyy - rmcbjenlme) View more | ||||||
NCT04122716 (Pubmed) Manual | Phase 4 | Obesity Maintenance | 109 | Supervised exercise | (pyubwzkuld) = jpfimtctsk rstsyulbvk (hfieuoednz ) | Positive | 01 Mar 2024 |
sxzgqncpba(jlwbmaocyx) = koxybykgfk dygueevpun (aiqwmjuhki ) | |||||||
Not Applicable | 43 | (Liraglutide 1.8 mg) | zfzwixkjyi(zkfpaarkxb) = pbbfaltiin fqasnsypmm (whaxoauahl, dbmprhfykw - xgngexkrbe) View more | - | 29 Feb 2024 | ||
Placebo (Placebo) | zfzwixkjyi(zkfpaarkxb) = pogcfftbzr fqasnsypmm (whaxoauahl, ncrbiupogj - iazbecpmuk) View more |